Roughly 30,000 Americans are diagnosed with multiple myeloma each year—a rare but serious cancer of the plasma cells. Historically treated with chemotherapy, patients often faced recurring disease and…
Kidney cancer affects over 80,000 Americans annually, with renal cell carcinoma as the dominant type. Benjamin R. Lee, MD, MBA, outlines current AUA guideline recommendations, including when to…
A new multicenter study hopes to ascertain whether the adjuvant implementation of personalized cancer vaccine mRNA-4157, in combination with pembrolizumab, improves recurrence-free survival (RFS) when compared with pembrolizumab…
Trainees Luke J. Rogers, Akshay Patel, and Ruth Benson discuss the CovidSurg database, which includes any patient having an operation who tested positive for COVID-19 prior to or…
A treatment is undergoing development in hopes to receive FDA clearance to be the first drug targeted at the third- and fourth-line space in patients with refractory renal cell carcinoma…
Can targeted therapies offer safer and more efficient means to treat patients with acute myeloid leukemia (AML)? Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park…
Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, describes acute myeloid leukemia (AML) and details how emerging targeted treatments are transforming the…
In this interview, Omid Hamid, MD, discusses the current landscape of targeted therapies in melanoma. He shares his thoughts about immune response, triplet therapy, and soon-to-be-released data that…
Mark M. Awad, MD, PhD, assistant professor of Medicine at Harvard Medical School and clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute, shares insights…
In this “Practice Pearls” roundtable organized by Pharmacy Times, expert panelists discuss acute myeloid leukemia (AML) diagnosis and the various factors affecting decision-making for specialists treating patients with…
Paula J. Bates, PhD, professor of medicine at the University of Louisville School of Medicine, and colleagues John O. Trent, PhD, and Donald M. Miller, MD, PhD, have…
A study published in Clinical Cancer Research, authored by James Brugarolas, MD, PhD, professor of internal medicine (hematology/oncology) and director of the Kidney Cancer Program at UT Southwestern, demonstrated…
